JPH10513436A - カルシウム受容体活性化合物 - Google Patents
カルシウム受容体活性化合物Info
- Publication number
- JPH10513436A JPH10513436A JP8514118A JP51411895A JPH10513436A JP H10513436 A JPH10513436 A JP H10513436A JP 8514118 A JP8514118 A JP 8514118A JP 51411895 A JP51411895 A JP 51411895A JP H10513436 A JPH10513436 A JP H10513436A
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- cells
- compound
- calcium
- substituents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/28—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by unsaturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
- C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式; [式中、Ar1は、所望により、低級アルキル、ハロゲン、低級アルコキシ、低級 チオアルキル、メチレンジオキシ、低級ハロアルキル、低級ハロアルコキシ、O H、CH2OH、CONH2、CN、アセトキシ、N(CH3)2、フェニル、フェノ キシ、ベンジル、ベンジルオキシ、α,α−ジメチルベンジル、NO2、CHO、 CH3CH(OH)、アセチル、エチレンジオキシからなる群より、各々、独立し て選択される0ないし5個の置換基で置換されていてもよいナフチルまたはフェ ニルのいずれかであり; Ar2は、所望により、低級アルキル、ハロゲン、低級アルコキシ、低級チオア ルキル、メチレンジオキシ、低級ハロアルキル、低級ハロアルコキシ、OH、C H2OH、CONH2、CNおよびアセトキシからなる群より、各々、独立して選 択される0ないし5個の置換基で置換されていてもよいナフチルまたはフェニル のいずれかであり; qは0、1、2または3であり;および RはHまたは低級アルキルのいずれかである] で示される無機物イオン受容体を調節する化合物またはその医薬上の塩もしくは 複合物であって、1またはそれ以上の無機物イオン受容体活性を調節する化合物 。 2.Ar1がフェニルであり、あるならば、イソプロピル、CH3O、CF3、C H3S、CF3O、I、Cl、FおよびCH3からなる群より、各々独立して選択 される1ないし5個の置換基を有し、 Ar2がフェニルであり、あるならば、イソプロピル、CH3O、CH3S、CF3 O、I、Cl、F、CF3およびCH3からなる群より、各々独立して選択される 1ないし5個の置換基を有する化合物であって、 該化合物がカルシミメティックであり; その無機物イオン受容体活性がカルシウム受容体活性である請求項1記載の化 合物。 3.qが2であり、Ar1がフェニルであって、1ないし5個の置換基を有し、 Ar2がフェニルであって、1ないし5個の置換基を有する請求項2記載の化合物 。 4.Ar2のフェニルがメタメトキシフェニルである請求項3記載の化合物。 5.qが0であり、Ar2がナフチルである請求項2記載の化合物。 6.Ar1がフェニルであり、1ないし5個の置換基を有する請求項5記載の化 合物。 7.qが2であり、Ar1がフェニルであって、1ないし5個の置換基を有し、 Ar2がナフチルである請求項2記載の化合物。 8.Ar1がフェニルであり、あるならば、CF3O、I、Cl、FおよびCF3 からなる群より、各々独立して選択される1ないし5個の置換基を有し、 Ar2がフェニルであり、あるならば、CF3O、I、Cl、F、CH3Oおよび CF3からなる群より、各々独立して選択される1ないし5個の置換基を有する 請求項2記載の化合物。 9.Ar1がフェニルであり、CF3O、I、Cl、FおよびCF3からなる群よ り、各々独立して選択される1ないし5個の置換基を有し、 Ar2がフェニルであり、CF3O、I、Cl、F、CH3OおよびCF3からなる 群より、各々独立して選択される1ないし5個の置換基を有する請求項3記載の 化合物。 10.Ar2のフェニルがメタメトキシフェニルである請求項9記載の化合物。 11.RがCH3である請求項2記載の化合物。 12.RがCH3である請求項3記載の化合物。 13.RがCH3である請求項4記載の化合物。 14.RがCH3である請求項7記載の化合物。 15.式: で示される化合物またはその医薬上許容される塩もしくは複合体である請求項1 1記載の化合物。 16.式: [式中、Ar3は、所望により、低級アルキル、ハロゲン、低級アルコキシ、低級 チオアルキル、メチレンジオキシ、低級ハロアルキル、低級ハロアルコキシ、O H、CH2OH、CONH2、CN、アセトキシ、ベンジル、ベンジルオキシ、ジ メチルベンジル、NO2、CHO、CH3CH(OH)、N(CH3)2、アセチル、エ チレンジオキシからなる群より、各々、独立して選択される0ないし5個の置換 基で置換されていてもよいナフチルまたはフェニルのいずれかであり; Ar4は、所望により、低級アルキル、ハロゲン、低級アルコキシ、低級チオア ルキル、メチレンジオキシ、低級ハロアルキル、低級ハロアルコキシ、OH、 CH2OH、CONH2、CNおよびアセトキシからなる群より、各々、独立して 選択される0ないし5個の置換基で置換されていてもよいナフチルまたはフェニ ルのいずれかであり; R8は水素またはフェニルのいずれかであり; R9は水素またはメチルのいずれかであり;および R10は水素、メチルまたはフェニルのいずれかを意味する] で示される無機物イオン受容体を調節する化合物またはその医薬上許容される塩 および複合体。 17.式: [式中、Ar5は、所望により、低級アルキル、ハロゲン、低級アルコキシ、低級 チオアルキル、メチレンジオキシ、低級ハロアルキル、低級ハロアルコキシ、O H、CH2OH、CONH2、CN、アセトキシ、ベンジル、ベンジルオキシ、α ,α−ジメチルベンジル、NO2、CHO、CH3CH(OH)、アセチル、エチレ ンジオキシ、−CH=CH−フェニルからなる群より、各々、独立して選択され る0ないし5個の置換基で置換されていてもよいナフチルまたはフェニルのいず れかであり; Ar6は、所望により、アセチル、低級アルキル、ハロゲン、低級アルコキシ、 低級チオアルキル、メチレンジオキシ、低級ハロアルキル、低級ハロアルコキシ 、OH、CH2OH、CONH2、CN、カルボメトキシ、OCH2C(O)C2H5 およびアセトキシからなる群より、各々、独立して選択される0ないし5個の置 換基で置換されていてもよいナフチルまたはフェニルのいずれかであり; R11は水素またはメチルであり;および R12は水素またはメチルを意味する] で示される無機物イオン受容体を調節する化合物。 18.請求項1〜17のいずれかに記載の化合物と、医薬上許容される担体とを 含有してなる医薬組成物。 19.かかる治療を必要とする患者の治療法であって、治療学上有効量の請求項 18に記載の医薬組成物をその患者に投与する工程からなることを特徴とする方 法。 20.患者がヒトであり、その疾患が、(1)異常なカルシウムホメオスタシス 、および(2)その産生がカルシウム受容体活性により影響を受ける得る細胞外 または細胞内メッセンジャーの異常な量、のいずれか一方または両方で特徴付け られ、該化合物がカルシミメティックである請求項19記載の方法。 21.患者がヒトであり、疾患が一次および二次副甲状腺機能亢進症、パジェッ ト病、悪性高カルシウム血症、骨粗鬆症、高血圧症および腎性骨形成異常症から なる群より選択される請求項19記載の方法。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1994/012117 WO1995011221A1 (en) | 1991-08-23 | 1994-10-21 | Calcium receptor-active arylalkyl amines |
US353,784 | 1994-12-08 | ||
US08/353,784 US6011068A (en) | 1991-08-23 | 1994-12-08 | Calcium receptor-active molecules |
US94/12117 | 1994-12-08 | ||
US08/353,784 | 1994-12-08 | ||
PCT/US1995/013704 WO1996012697A2 (en) | 1994-10-21 | 1995-10-23 | Calcium receptor-active compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10513436A true JPH10513436A (ja) | 1998-12-22 |
JP2882882B2 JP2882882B2 (ja) | 1999-04-12 |
Family
ID=23390556
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8514118A Expired - Lifetime JP2882882B2 (ja) | 1994-10-21 | 1995-10-23 | カルシウム受容体活性化合物 |
JP01656398A Expired - Fee Related JP4002338B2 (ja) | 1994-10-21 | 1998-01-29 | カルシウム受容体活性化合物 |
JP2007042364A Expired - Fee Related JP4353985B2 (ja) | 1994-10-21 | 2007-02-22 | カルシウム受容体活性化合物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP01656398A Expired - Fee Related JP4002338B2 (ja) | 1994-10-21 | 1998-01-29 | カルシウム受容体活性化合物 |
JP2007042364A Expired - Fee Related JP4353985B2 (ja) | 1994-10-21 | 2007-02-22 | カルシウム受容体活性化合物 |
Country Status (25)
Country | Link |
---|---|
US (1) | US6211244B1 (ja) |
EP (4) | EP1275635A1 (ja) |
JP (3) | JP2882882B2 (ja) |
KR (2) | KR100293621B1 (ja) |
CN (2) | CN1147459C (ja) |
AT (2) | ATE359259T1 (ja) |
AU (1) | AU709303B2 (ja) |
BR (1) | BRPI9509411B8 (ja) |
CA (1) | CA2202879C (ja) |
CZ (2) | CZ290670B6 (ja) |
DE (4) | DE69535461T2 (ja) |
DK (1) | DK1203761T3 (ja) |
ES (2) | ES2234768T3 (ja) |
FR (1) | FR05C0029I2 (ja) |
HK (4) | HK1002454A1 (ja) |
HU (2) | HU228150B1 (ja) |
LU (1) | LU91182I2 (ja) |
NL (1) | NL300199I2 (ja) |
NZ (1) | NZ297157A (ja) |
PL (1) | PL183499B1 (ja) |
PT (1) | PT1203761E (ja) |
RU (1) | RU2195446C2 (ja) |
TW (2) | TW200402407A (ja) |
UA (1) | UA55374C2 (ja) |
WO (1) | WO1996012697A2 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001106661A (ja) * | 1999-08-04 | 2001-04-17 | Sumitomo Chem Co Ltd | アミン化合物、中間体、製造法および光学分割剤 |
JP2005530811A (ja) * | 2002-05-23 | 2005-10-13 | アムジエン・インコーポレーテツド | カルシウム受容体修飾物質 |
JP2009507017A (ja) * | 2005-09-02 | 2009-02-19 | アムジエン・インコーポレーテツド | 腸液バランスを調節する方法 |
WO2009107579A1 (ja) * | 2008-02-25 | 2009-09-03 | 味の素株式会社 | コク味付与剤 |
JP2009534425A (ja) * | 2006-04-20 | 2009-09-24 | アムゲン インコーポレイティッド | 安定乳化製剤 |
WO2010150837A1 (ja) * | 2009-06-25 | 2010-12-29 | 第一三共株式会社 | インドリン誘導体 |
JP2012523418A (ja) * | 2009-04-09 | 2012-10-04 | コグニション セラピューティクス インク. | 認知機能低下の阻害剤 |
JP2015528462A (ja) * | 2012-08-27 | 2015-09-28 | ルピン・リミテッドLupin Limited | カルシウム感知受容体モジュレーターとしてのアリールアルキルアミン化合物 |
US10207991B2 (en) | 2014-01-31 | 2019-02-19 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
Families Citing this family (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
EP1275635A1 (en) * | 1994-10-21 | 2003-01-15 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
WO1997005252A2 (en) * | 1995-07-26 | 1997-02-13 | Nps Pharmaceuticals, Inc. | Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases |
ES2326004T3 (es) * | 1996-05-01 | 2009-09-28 | Nps Pharmaceuticals, Inc. | Compuestos activos de receptor de ion inorganico. |
EP1258471B1 (en) * | 1996-05-01 | 2007-01-24 | Nps Pharmaceuticals, Inc. | Inorganic ion receptor-active compounds |
EP1770083B1 (en) * | 1996-05-01 | 2009-04-29 | Nps Pharmaceuticals, Inc. | Inorganic ion receptor-active compounds |
JP4331264B2 (ja) | 1996-07-08 | 2009-09-16 | 協和発酵キリン株式会社 | カルシウムレセプター活性化合物 |
US6210964B1 (en) * | 1997-08-18 | 2001-04-03 | The Brigham And Women's Hospital, Inc. | Avian extracellular calcium-sensing receptor |
AU760889B2 (en) | 1998-10-14 | 2003-05-22 | Ortho-Mcneil Pharmaceutical, Inc. | 1,2-disubstituted cyclopropanes |
US20040214889A1 (en) * | 1999-07-31 | 2004-10-28 | Smithkline Beecham Corporation | Calcilytic compounds |
EP1074539B1 (en) * | 1999-08-04 | 2007-10-17 | Sumitomo Chemical Company, Limited | Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof |
US6797842B2 (en) * | 2000-05-11 | 2004-09-28 | Central Glass Company, Limited | Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same |
FR2809396B1 (fr) * | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
AR038658A1 (es) * | 2001-06-15 | 2005-01-26 | Novartis Ag | Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento |
US6908935B2 (en) | 2002-05-23 | 2005-06-21 | Amgen Inc. | Calcium receptor modulating agents |
US6849761B2 (en) | 2002-09-05 | 2005-02-01 | Wyeth | Substituted naphthoic acid derivatives useful in the treatment of insulin resistance and hyperglycemia |
GB0230015D0 (en) * | 2002-12-23 | 2003-01-29 | Novartis Ag | Organic compounds |
US7105537B2 (en) * | 2003-01-28 | 2006-09-12 | Bristol-Myers Squibb Company | 2-substituted cyclic amines as calcium sensing receptor modulators |
US7205322B2 (en) * | 2003-02-12 | 2007-04-17 | Bristol-Myers Squibb Company | Thiazolidine compounds as calcium sensing receptor modulators |
US7265145B2 (en) * | 2003-05-28 | 2007-09-04 | Bristol-Myers Squibb Company | Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method |
FR2855754B1 (fr) * | 2003-06-05 | 2005-07-08 | Oreal | Compsition, notamment cosmetique, comprenant une amine carbonylee |
ES2655435T3 (es) * | 2003-09-12 | 2018-02-20 | Amgen Inc. | Formulación de disolución rápida de cinacalcet |
US20050186658A1 (en) * | 2003-10-17 | 2005-08-25 | Nps Pharmaceuticals, Inc. | Chimeric metabotropic glutamate receptors and uses thereof |
JP4629036B2 (ja) | 2004-05-28 | 2011-02-09 | 田辺三菱製薬株式会社 | アリールアルキルアミン化合物及びその製法 |
US20050288377A1 (en) * | 2004-06-14 | 2005-12-29 | Cantor Thomas L | Use of calcimimetic as an adynamic bone disease related treatment |
JP2008506746A (ja) * | 2004-07-22 | 2008-03-06 | ディーエスエム アイピー アセッツ ビー.ブイ. | ジアステレオマーに富んだ化合物の調製方法 |
US7361789B1 (en) | 2004-07-28 | 2008-04-22 | Amgen Inc. | Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis |
US20060276534A1 (en) * | 2005-03-17 | 2006-12-07 | Amgen Inc. | Methods of decreasing calcification |
FR2885129B1 (fr) * | 2005-04-29 | 2007-06-15 | Proskelia Sas | Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation. |
WO2006125026A2 (en) * | 2005-05-16 | 2006-11-23 | Teva Pharmaceutical Industries, Ltd. | Process for preparing cinacalcet hydrochloride |
ES2334260T3 (es) * | 2005-05-23 | 2010-03-08 | Teva Pharmaceutical Industries Ltd. | Procedimientos para la preparacion de la forma i cristalina de clorhidrato de cinacalcet. |
MX2007000982A (es) * | 2005-05-23 | 2007-04-16 | Teva Pharma | Clorhidrato de cinacalcet amorfo y preparacion del mismo. |
US7595161B2 (en) | 2005-11-10 | 2009-09-29 | Hansjoerg Martin Rothe | Efficacy of calcimimetic agents |
US7563930B2 (en) * | 2005-11-22 | 2009-07-21 | Teva Pharmaceutical Industries Ltd | Crystal forms of Cinacalcet HCI and processes for their preparation |
ES2335360T3 (es) | 2005-11-25 | 2010-03-25 | Galapagos Sas | Derivados de urea utiles como moduladores de los receptores de calcio. |
US20070129444A1 (en) * | 2005-12-06 | 2007-06-07 | Mallinckrodt Inc. | Novel weight reduction composition and uses thereof |
EP3095447B1 (en) | 2006-02-03 | 2021-11-24 | OPKO Renal, LLC | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
AU2007230724B2 (en) | 2006-03-23 | 2014-01-30 | Amgen Inc. | Methods and compositions for making and using polymorphs of cinacalcet |
TW200811082A (en) * | 2006-04-27 | 2008-03-01 | Teva Pharma | Process for the preparation of cinacalcet base |
ATE447546T1 (de) * | 2006-04-27 | 2009-11-15 | Teva Pharma | Verfahren zur herstellung einer cinacalcetbase |
PT2037936E (pt) | 2006-06-21 | 2014-09-04 | Opko Renal Llc | Método de tratamento e prevenção do hiperparatiroidismo secundário |
WO2008000422A1 (en) * | 2006-06-27 | 2008-01-03 | Sandoz Ag | Amorphous form of cinacalcet |
WO2008000423A1 (en) * | 2006-06-27 | 2008-01-03 | Sandoz Ag | Crystalline form of cinacalcet |
EP1914224A1 (en) * | 2006-10-19 | 2008-04-23 | Sandoz AG | Amorphous organic compound |
GB0613674D0 (en) * | 2006-07-10 | 2006-08-16 | Proskelia Sas | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
WO2008027522A2 (en) * | 2006-09-01 | 2008-03-06 | Teva Pharmaceutical Industries Ltd. | Solid composites of a calicum receptor-active compound |
CN101547922B (zh) * | 2006-10-04 | 2012-06-20 | 辉瑞产品公司 | 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物 |
JP5470653B2 (ja) * | 2006-10-26 | 2014-04-16 | アムジエン・インコーポレーテツド | カルシウム受容体調節剤 |
WO2008058236A2 (en) * | 2006-11-08 | 2008-05-15 | Dr. Reddy's Labortories, Ltd. | Methods for preparing cinacalcet hydrochloride |
US20080146845A1 (en) * | 2006-11-20 | 2008-06-19 | Boaz Gome | Process for preparing Cinacalcet |
CA2672560A1 (en) * | 2006-12-15 | 2008-06-26 | Ruprecht-Karls-Universitaet Heidelberg | Methods for treating podocyte-related disorders |
CA2681582C (en) | 2007-03-30 | 2015-07-14 | Amgen Inc. | Methods of treating bowel disorders |
CA2701638A1 (en) * | 2007-04-02 | 2008-10-09 | Concert Pharmaceuticals Inc. | Pharmaceutical calcimimetics |
US11752158B2 (en) | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
CN104523707B (zh) | 2007-04-25 | 2022-08-26 | 欧普科Ip 控股Ii 有限公司 | 包含维生素d化合物和蜡质载体的口服控释组合物 |
WO2008139947A1 (ja) * | 2007-05-08 | 2008-11-20 | Ajinomoto Co., Inc. | 下痢の予防又は治療剤 |
CA2691196C (en) * | 2007-06-21 | 2016-05-24 | Amgen Inc. | Methods of synthesizing cinacalcet and salts thereof |
ITMI20071261A1 (it) * | 2007-06-22 | 2008-12-23 | Dipharma Francis Srl | Procedimento per la preparazione di cinacalcet |
AU2008275595B2 (en) * | 2007-07-10 | 2013-11-14 | Amgen Inc. | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
WO2009025792A2 (en) * | 2007-08-16 | 2009-02-26 | Teva Pharmaceutical Industries Ltd. | Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof |
AU2008328362A1 (en) * | 2007-11-23 | 2009-05-28 | Leo Pharma A/S | Novel cyclic hydrocarbon compounds for the treatment of diseases |
WO2009107660A1 (ja) | 2008-02-25 | 2009-09-03 | 味の素株式会社 | 糖尿病又は肥満病の予防又は治療剤 |
WO2009119554A1 (ja) * | 2008-03-24 | 2009-10-01 | 味の素株式会社 | 消化管の重炭酸分泌促進剤 |
US8609655B2 (en) * | 2008-03-28 | 2013-12-17 | Amgen Inc. | Calcimimetic compound for use in the treatment of epithelial injury |
JP5533648B2 (ja) | 2008-04-17 | 2014-06-25 | 味の素株式会社 | 免疫賦活剤 |
US8614354B2 (en) * | 2008-06-18 | 2013-12-24 | Erregierre S.P.A. | Process for the synthesis of cinacalcet hydrochloride |
US20110178326A1 (en) * | 2008-08-06 | 2011-07-21 | Actavis Group Ptc Ehf | Unsaturated cinacalcet salts and processes for preparing cinacalcet hydrochloride |
US9133140B2 (en) | 2008-08-22 | 2015-09-15 | Daiichi Sankyo Company, Limited | Cycloalkylamne derivatives |
WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
US20110318417A1 (en) * | 2008-12-08 | 2011-12-29 | Actavis Group Ptc Ehf | Highly pure cinacalcet or a pharmaceutically acceptable salt thereof |
US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
WO2010086129A1 (en) | 2009-01-27 | 2010-08-05 | Rathiopharm Gmbh | Inclusion complex comprising cinacalcet and cyclodextrin |
AU2010215520B2 (en) | 2009-02-19 | 2016-07-21 | F.I.S. - Fabbrica Italiana Sintetici S.P.A. | Process for preparing Cinacalcet hydrochloride |
CA2754209A1 (en) | 2009-03-05 | 2010-09-10 | Cipla Limited | Process for the preparation of cinacalcet and salts thereof, and intermediates for use in the process |
EP2406211B1 (en) | 2009-03-09 | 2018-06-27 | Megafine Pharma (P) Ltd. | A new method for the preparation of cinacalcet and new intermediates thereof |
WO2010103429A1 (en) | 2009-03-10 | 2010-09-16 | Pfizer Inc. | 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists |
WO2010104882A1 (en) | 2009-03-10 | 2010-09-16 | Amgen Inc. | Methods of modulating sperm motility |
WO2010128388A2 (en) | 2009-05-08 | 2010-11-11 | Aurobindo Pharma Limited | An improved process for the preparation of intermediate compounds useful for the preparation of cinacalcet |
WO2010136037A1 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
US8785494B2 (en) | 2009-05-27 | 2014-07-22 | Leo-Pharma A/S | Calcium sensing receptor modulating compounds and pharmaceutical use thereof |
EP2458983B1 (en) | 2009-07-31 | 2015-07-08 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
ES2445532T3 (es) | 2009-09-10 | 2014-03-03 | Zach System S.P.A. | Proceso para preparar cinacalcet |
US8759586B2 (en) | 2009-09-16 | 2014-06-24 | Ranbaxy Laboratories Limited | Processes for the preparation of cinacalcet |
MX338041B (es) | 2009-09-25 | 2016-03-30 | Oryzon Genomics Sa | Inhibidores de demetilasa-1 especificos de lisina y su uso. |
US8722732B2 (en) | 2009-09-29 | 2014-05-13 | Nektar Therapeutics | Oligomer-calcimimetic conjugates and related compounds |
WO2011056325A2 (en) | 2009-09-29 | 2011-05-12 | Nektar Therapeutics | Oligomer-calcimimetic conjugates and related compounds |
US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
EP2314286A1 (de) | 2009-10-21 | 2011-04-27 | Ratiopharm GmbH | Schmelzgranuliertes Cinacalcet |
CN102119137A (zh) * | 2009-11-02 | 2011-07-06 | 上海威智医药科技有限公司 | 盐酸西那卡塞的合成方法 |
IT1396623B1 (it) | 2009-11-26 | 2012-12-14 | Dipharma Francis Srl | Procedimento per la preparazione di cinacalcet e suoi intermedi |
US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
WO2011123476A1 (en) | 2010-03-29 | 2011-10-06 | Cytochroma Inc. | Methods and compositions for reducing parathyroid levels |
ES2607081T3 (es) | 2010-04-19 | 2017-03-29 | Oryzon Genomics, S.A. | Inhibidores de desmetilasa específica de lisina-1 y su uso |
WO2011146583A2 (en) | 2010-05-19 | 2011-11-24 | Elan Pharma International Limited | Nanoparticulate cinacalcet formulations |
RU2599788C2 (ru) * | 2010-06-30 | 2016-10-20 | Лео Фарма А/С | Новая полиморфная форма кальцимиметического соединения |
EP2588445A1 (en) * | 2010-06-30 | 2013-05-08 | Leo Pharma A/S | New polymorphic form of a calcimimetic compound |
US8921606B2 (en) * | 2010-07-16 | 2014-12-30 | Hetero Research Foundation | Process for cinacalcet hydrochloride |
EP2598480B1 (en) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
LT2598482T (lt) | 2010-07-29 | 2018-07-10 | Oryzon Genomics, S.A. | Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas |
WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
CN101993379B (zh) * | 2010-10-22 | 2013-06-19 | 能特科技股份有限公司 | 一种盐酸西那卡塞的制备方法 |
US20130261132A1 (en) | 2010-11-26 | 2013-10-03 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
JP2014508104A (ja) | 2010-11-26 | 2014-04-03 | レオ ファーマ アクティーゼルスカブ | カルシウム感知受容体活性化合物 |
JP2014500882A (ja) | 2010-11-26 | 2014-01-16 | レオ ファーマ アクティーゼルスカブ | カルシウム感知受容体活性化合物 |
US20130245084A1 (en) | 2010-11-26 | 2013-09-19 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
EP2651448B1 (en) | 2010-12-13 | 2018-11-28 | QuiaPEG Pharmaceuticals AB | Water-soluble, non-peptidic, non-nucleotidic phosphoramidate functionalized polymers |
WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
BR112014009306B1 (pt) | 2011-10-20 | 2021-07-20 | Oryzon Genomics S.A. | Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1 |
CA2849564C (en) | 2011-10-20 | 2020-10-20 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
CZ303627B6 (cs) | 2011-11-25 | 2013-01-16 | Zentiva, K.S. | Zpusob výroby Cinacalcetu |
CN103450027B (zh) | 2012-05-29 | 2015-07-29 | 上海京新生物医药有限公司 | 盐酸西那卡塞的制备方法 |
CA2876315C (en) | 2012-06-12 | 2021-05-25 | Marek Kwiatkowski | Conjugates of biologically active molecules to functionalized polymers |
WO2014031755A1 (en) * | 2012-08-21 | 2014-02-27 | The Board Of Regents Of The University Of Texas System | Fendiline derivatives and methods of use thereof |
FR2995307A1 (fr) | 2012-09-07 | 2014-03-14 | Prod Chim Auxiliaires Et De Synthese | Procede de preparation du cinacalcet et de ses sels pharmaceutiquement acceptables |
PL2730279T3 (pl) | 2012-11-09 | 2015-12-31 | K H S Pharma Holding Gmbh | Preparaty cynakalcetu o natychmiastowym uwalnianiu |
WO2014096277A1 (en) | 2012-12-21 | 2014-06-26 | Synthon B.V. | Tablet composition comprising cinacalcet hydrochloride |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
CA2915432C (en) | 2013-06-26 | 2019-03-05 | Jubilant Life Sciences Limited | Disintegrant free composition of cinacalcet |
EP3148972B1 (en) | 2014-05-27 | 2019-08-21 | Cardioxyl Pharmaceuticals, Inc. | Pyrazolone derivatives as nitroxyl donors |
CN104045568A (zh) * | 2014-06-18 | 2014-09-17 | 中山奕安泰医药科技有限公司 | 一种合成(r)-1–(萘-1-基)乙胺的新工艺 |
CR20170085A (es) | 2014-08-07 | 2017-04-25 | Opko Ireland Global Holdings Ltd | Terapia adjuntiva con 25-hidroxi vitamina d |
CN104478736B (zh) * | 2014-12-16 | 2016-07-13 | 成都启泰医药技术有限公司 | 一种盐酸西那卡塞的制备方法 |
US20180155270A1 (en) | 2015-05-29 | 2018-06-07 | Lupin Limited | Process for preparation of cinacalcet intermediate and cinacalcet hydrochloride |
KR20180123100A (ko) | 2016-03-28 | 2018-11-14 | 옵코 아일랜드 글로벌 홀딩스 리미티드 | 비타민 d 치료 방법 |
EP4011396A1 (en) | 2017-03-10 | 2022-06-15 | QuiaPEG Pharmaceuticals AB | Releasable conjugates |
BR112019023851A2 (pt) | 2017-05-15 | 2020-08-18 | Cognition Therapeutics, Inc. | compostos, suas composições farmacêuticas e métodos para tratamento de doenças neurodegenerativas |
JP2021535920A (ja) | 2018-09-12 | 2021-12-23 | キアペグ ファーマシューティカルズ アクチエボラグ | 放出可能なglp−1コンジュゲート |
CN111196759B (zh) * | 2018-11-16 | 2023-03-24 | 上海博志研新药物技术有限公司 | 盐酸西那卡塞及其中间体的制备方法 |
MX2022002282A (es) * | 2019-08-28 | 2022-03-25 | Unilever Ip Holdings B V | Compuestos novedosos para aclarar la piel. |
WO2021191417A1 (en) | 2020-03-27 | 2021-09-30 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of synucleinopathies |
RU2739376C1 (ru) * | 2020-07-24 | 2020-12-23 | Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) | Способ получения фендилина |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2276618A (en) | 1942-03-17 | N-phenylaliphatic bihxdroxithenyl- | ||
US2930731A (en) | 1952-04-08 | 1960-03-29 | Upjohn Co | Bis[beta-(ortho-hydrocarbonoxyphenyl)iso-propyl]amines |
BE570596A (ja) | 1957-08-26 | |||
BE621300A (ja) | 1961-08-14 | |||
US3262977A (en) | 1962-03-10 | 1966-07-26 | Chinoin Gyogyszer Es Vegyeszet | N-aralkyl-1, 1-diphenyl-propylamine derivatives |
NL293886A (ja) | 1962-06-19 | 1965-04-12 | Merck Ag E | |
US3318952A (en) * | 1964-01-22 | 1967-05-09 | Sandoz Ag | Dibenzylsulfamides |
US3459767A (en) | 1965-08-10 | 1969-08-05 | Pfizer & Co C | Aminomethylindoles |
GB1109924A (en) | 1965-11-29 | 1968-04-18 | Roche Products Ltd | Novel substituted diphenylalkyl amines and a process for the manufacture thereof |
DE1618005A1 (de) | 1966-09-22 | 1971-09-09 | Thomae Gmbh Dr K | Verfahren zur Herstellung von neuen Amino-dihalogen-phenyl-aethylaminen |
CH480791A (de) | 1967-01-17 | 1969-11-15 | Ciba Geigy | Schädlingsbekämpfungsmittel |
GB1263987A (en) | 1969-05-30 | 1972-02-16 | Allen & Hanburys Ltd | Phenethylamine derivatives |
US4129598A (en) * | 1972-05-31 | 1978-12-12 | Synthelabo | Phenylethylamine derivatives |
GB1448437A (en) | 1973-02-24 | 1976-09-08 | Beecham Group Ltd | Diphenylpropylamines |
US3862925A (en) | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
US4000197A (en) * | 1973-07-23 | 1976-12-28 | The University Of Iowa Research Foundation | Asymmetric synthesis of phenylisopropylamines |
US3842067A (en) | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
JPS5726506B2 (ja) | 1974-03-08 | 1982-06-04 | ||
US4014937A (en) | 1974-08-26 | 1977-03-29 | Pfizer Inc. | 3,4-And 3,5-dialkoxyphenethylamines |
HU169507B (ja) * | 1974-09-25 | 1976-12-28 | ||
US3987201A (en) | 1974-12-24 | 1976-10-19 | Eli Lilly And Company | Method for treating arrhythmia |
US4105602A (en) | 1975-02-10 | 1978-08-08 | Armour Pharmaceutical Company | Synthesis of peptides with parathyroid hormone activity |
JPS5390272A (en) | 1977-01-13 | 1978-08-08 | Sendai Fukusokan Kagaku Kenkiy | Method of producing optically active salsolizine |
US4608391A (en) | 1977-07-05 | 1986-08-26 | Cornell Research Foundation Inc. | Catecholamine derivatives, a process for their preparation and pharmaceutical compositions thereof |
US4289787A (en) | 1977-12-19 | 1981-09-15 | Eli Lilly And Company | Quaternary ammonium antiarrhythmic drugs |
DD144050A5 (de) | 1978-06-05 | 1980-09-24 | Ciba Geigy Ag | Verfahren zur herstellung von n-alkylierten aminoalkoholen |
DE2825961A1 (de) | 1978-06-14 | 1980-01-03 | Basf Ag | Fungizide amine |
CA1142954A (en) | 1978-07-03 | 1983-03-15 | Jack Mills | Phenethanolamines, compositions containing the same, and method for effecting weight control |
US4391826A (en) | 1978-07-03 | 1983-07-05 | Eli Lilly And Company | Phenethanolamines, compositions containing the same, and method for effecting weight control |
ZA794872B (en) | 1978-09-20 | 1980-11-26 | Schering Corp | A phenylalkylaminoethylsalicylamide,its preparation and pharmaceutical compositions containing it |
FR2436773A1 (fr) | 1978-09-22 | 1980-04-18 | Roussel Uclaf | Nouveaux derives du 3-(aminoethyl) phenol et leurs sels, procede de preparation et application a titre de medicaments |
DE2841184C2 (de) * | 1978-09-22 | 1986-09-25 | Hochtemperatur-Reaktorbau GmbH, 4600 Dortmund | Vorrichtung zur Durchmischung der Heißgassträhnen bei einem gasgekühlten Hochtemperaturreaktor |
US4360511A (en) | 1978-11-29 | 1982-11-23 | Medi-Physics, Inc. | Amines useful as brain imaging agents |
DD150456A5 (de) | 1979-03-01 | 1981-09-02 | Ciba Geigy Ag | Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols |
EP0023385B1 (en) | 1979-06-16 | 1982-12-15 | Beecham Group Plc | Ethanamine derivatives, their preparation and use in pharmaceutical compositions |
JPS603387B2 (ja) | 1980-07-10 | 1985-01-28 | 住友化学工業株式会社 | 新規光学活性イミダゾリジン−2−オン誘導体およびその製法 |
HU183430B (en) | 1981-05-12 | 1984-05-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing cyclodextrine inclusion complexes of n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine or n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine-hydrochloride |
US4591605A (en) | 1981-11-10 | 1986-05-27 | Research Foundation Of State University Of New York | Method and ingestible formulation for inhibiting the secretion of stomach acid |
US4658060A (en) | 1982-04-26 | 1987-04-14 | Schering Corporation | Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide |
DE3225879A1 (de) | 1982-07-10 | 1984-01-12 | Basf Ag, 6700 Ludwigshafen | Trans-3-(4'-tert.-butylcyclohexyl-1')-2-methyl-1-dialkyl-aminopropane, ihre herstellung und verwendung als arzneimittel |
CA1258454A (en) | 1982-08-10 | 1989-08-15 | Leo Alig | Phenethanolamines |
US4647446A (en) | 1982-08-18 | 1987-03-03 | The Regents Of The University Of California | Rapid brain scanning radiopharmaceutical |
JPS5950358A (ja) | 1982-09-14 | 1984-03-23 | Sumitomo Chem Co Ltd | 光学活性なカルボン酸をグラフトしたクロマトグラフ充填剤およびそれを用いる鏡像体混合物の分離法 |
US4677101A (en) | 1983-09-26 | 1987-06-30 | Merck & Co., Inc. | Substituted dihydroazepines useful as calcium channel blockers |
US4661635A (en) | 1983-11-21 | 1987-04-28 | Mcneilab, Inc. | Aralykyl (arylethynyl)aralkyl amines and their use as vasodilators and antihypertensives |
DE3405333A1 (de) * | 1984-02-15 | 1985-08-22 | Sandoz-Patent-GmbH, 7850 Lörrach | Neue allylamine, verfahren zu ihrer herstellung und ihre verwendung |
US5334628A (en) | 1984-06-09 | 1994-08-02 | Kaken Pharmaceutical Co., Ltd. | Amine derivatives, processes for preparing the same and fungicides containing the same |
US4587253A (en) | 1984-07-30 | 1986-05-06 | Merck & Co., Inc. | Bridged pyridine compounds useful as calcium channel blockers and analgesics |
US4609494A (en) | 1985-02-21 | 1986-09-02 | Merck & Co., Inc. | 5-acetyl-3,4,5,6-tetrahydro-4-oxo-2,6-methano-2H-1,3,5-benzothiazocine(benzodiazocine)-11-carboxylates useful as calcium channel blockers |
US4839369A (en) | 1985-04-16 | 1989-06-13 | Rorer Pharmaceutical Corporation | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments |
GB8522186D0 (en) | 1985-09-06 | 1985-10-09 | Erba Farmitalia | Cycloalkyl-substituted 4-aminophenyl derivatives |
DE3541181A1 (de) | 1985-11-21 | 1987-05-27 | Basf Ag | Propylamine, verfahren zu ihrer herstellung und ihre verwendung als fungizide |
US4675321A (en) | 1986-02-07 | 1987-06-23 | Merck & Co., Inc. | Substituted pyrimidines useful as calcium channel blockers |
US5034514A (en) | 1986-03-17 | 1991-07-23 | Cetus Corporation | Novel cross-linking agents |
US5030576A (en) | 1986-04-30 | 1991-07-09 | Genentech, Inc. | Receptors for efficient determination of ligands and their antagonists or agonists |
US4808718A (en) | 1986-05-06 | 1989-02-28 | Merck & Co., Inc. | Fused polycyclic and bridged compounds useful as calcium channel blockers |
HU200591B (en) | 1986-07-11 | 1990-07-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds |
US4797411A (en) | 1986-07-18 | 1989-01-10 | Farmitalia Carlo Erba S.P.A. | Cycloalkyl-substituted 4-pyridyl derivatives and use as aromatase inhibitors |
HU207280B (en) | 1986-09-25 | 1993-03-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them |
US5064657A (en) | 1986-10-20 | 1991-11-12 | University Of Utah | Spider toxins and methods for their use as blockers of amino acid receptor function |
US4925664A (en) | 1986-10-20 | 1990-05-15 | University Of Utah | Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function |
DE3782010T2 (de) | 1986-12-04 | 1993-02-18 | Toyo Jozo Kk | Vom calcitonin-gen abgeleitete peptidderivate. |
GB8720115D0 (en) | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
GB8709871D0 (en) | 1987-04-27 | 1987-06-03 | Turner R C | Peptides |
US4916145A (en) | 1987-07-10 | 1990-04-10 | Hoffmann-La Roche Inc. | Substituted n-[(pyridyl)alkyl]aryl-carboxamide |
EP0348490B1 (en) | 1988-01-11 | 1995-09-27 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
US5001251A (en) | 1988-01-15 | 1991-03-19 | E. R. Squibb & Sons, Inc. | Optical resolution of DL-3-acylthio-2-methylpropanoic acid |
AU3548089A (en) | 1988-04-04 | 1989-11-03 | Salk Institute Biotechnology/Industrial Associates, Inc., The | Calcium channel compositions and methods |
US5082837A (en) | 1988-06-28 | 1992-01-21 | Merrell Dow Pharmaceuticals | Lactamimides as calcium antagonists |
US4925873A (en) | 1988-09-01 | 1990-05-15 | E. R. Squibb & Sons, Inc. | Method of treating skin injuries using thromboxane A2 receptor antagonists |
JPH02200658A (ja) | 1989-01-28 | 1990-08-08 | Kumiai Chem Ind Co Ltd | N―(置換)ベンジルカルボン酸アミド誘導体及び除草剤 |
RU2005717C1 (ru) * | 1989-02-17 | 1994-01-15 | Такеда кемикал-индастриз Лтд | Способ получения производных аралкиламинов или их кислотно-аддитивных солей |
US5011834A (en) | 1989-04-14 | 1991-04-30 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | PCP receptor ligands and the use thereof |
DD298412A5 (de) | 1989-04-28 | 1992-02-20 | ������@���Kk�� | Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele |
AU5957390A (en) | 1989-07-03 | 1991-02-06 | New York University | Use of polyamines as ionic-channel regulating agents |
GB8915712D0 (en) | 1989-07-08 | 1989-08-31 | Macintyre Iain | Medical treatment |
US5021599A (en) | 1989-08-31 | 1991-06-04 | Serpentix Conveyor Corporation | Redox-responsive anion receptors |
US5053337A (en) | 1989-10-30 | 1991-10-01 | Neurogenetic Corporation | DNA encoding an α2B -adrenergic receptor |
CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
JP2818958B2 (ja) | 1990-02-23 | 1998-10-30 | 塩野義製薬株式会社 | 4―(4―アルコキシフェニル)―2―ブチルアミン誘導体およびその製造法 |
US5096908A (en) | 1990-05-04 | 1992-03-17 | Eli Lilly And Company | Method of inhibiting gastric acid secretion |
WO1992007829A1 (en) | 1990-11-02 | 1992-05-14 | The Upjohn Company | Indole-3-methanamines useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents |
JPH06506455A (ja) | 1991-02-08 | 1994-07-21 | ケンブリッジ・ニューロサイエンス・インコーポレイテッド | 神経伝達物質放出調節剤としてのグアニジン置換体及びその誘導体ならびに神経伝達物質放出遮断物質を同定するための新規な方法 |
US5312928A (en) | 1991-02-11 | 1994-05-17 | Cambridge Neuroscience | Calcium channel antagonists and methodology for their identification |
DE69206306T2 (de) * | 1991-04-08 | 1996-06-13 | Sumitomo Chemical Co | Optisch aktive Sekundär-Aminverbindung, Verfahren zur Herstellung einer optisch aktiven Sekundär-Aminverbindung und Verfahren zur Herstellung optisch aktiver Carbonsäure durch die Verwendung dieser Verbindung. |
US5688938A (en) | 1991-08-23 | 1997-11-18 | The Brigham & Women's Hospital, Inc. | Calcium receptor-active molecules |
JP2728564B2 (ja) * | 1991-08-23 | 1998-03-18 | エヌピーエス・ファーマシウティカルズ・インコーポレイテッド | カルシウム受容体活性化分子 |
US5763569A (en) | 1991-08-23 | 1998-06-09 | The Brigham And Women's Hospital, Inc | Calcium receptor-active molecules |
CA2173747C (en) | 1991-08-23 | 2006-05-23 | Edward F. Nemeth | Calcium receptor-active arylalkyl amines |
ATE161821T1 (de) | 1991-11-12 | 1998-01-15 | Pfizer | Azyklische ethylendiaminderivate als 'substance p rezeptor' antagonisten |
DE69217992T2 (de) | 1991-12-30 | 1997-06-12 | Janssen Pharmaceutica Nv | Alpha-substituierte benzenmethanamin-derivate |
AU3588693A (en) | 1992-01-29 | 1993-09-01 | Smithkline Beecham Corporation | N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as TNF and PDE IV inhibitors |
JP3175339B2 (ja) * | 1992-10-07 | 2001-06-11 | 住友化学工業株式会社 | 光学活性アミン化合物、その製法、その中間体及びその用途 |
RU2146132C1 (ru) | 1993-02-23 | 2000-03-10 | Брихэм энд Уимен З Хоспитал, Инк. | Фармацевтическая композиция, активная в отношении рецептора кальция, способ лечения пациента, способ анализа соединения оказывать влияние на активность рецептора неорганического иона, нуклеиновая кислота, кодирующая рецептор, рецептор кальция |
GB9326403D0 (en) | 1993-12-24 | 1994-02-23 | Oxford Asymmetry Ltd | Improvements in or relating to chiral syntheses |
US5631401A (en) * | 1994-02-09 | 1997-05-20 | Abbott Laboratories | Inhibitors of protein farnesyltransferase and squalene synthase |
EP1275635A1 (en) * | 1994-10-21 | 2003-01-15 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
US7043457B1 (en) | 2000-06-28 | 2006-05-09 | Probuild, Inc. | System and method for managing and evaluating network commodities purchasing |
US20060283332A1 (en) | 2001-12-11 | 2006-12-21 | Garman Michael H | Hot beverage maker |
US8526300B2 (en) | 2008-03-31 | 2013-09-03 | Ericsson Ab | Method and apparatus for providing resiliency in multicast networks |
KR101411428B1 (ko) | 2012-07-12 | 2014-06-24 | 한국과학기술원 | 집광식 휴대용 형광 검출 시스템 |
-
1995
- 1995-10-23 EP EP02019566A patent/EP1275635A1/en not_active Withdrawn
- 1995-10-23 NZ NZ297157A patent/NZ297157A/xx not_active IP Right Cessation
- 1995-10-23 AT AT95940547T patent/ATE359259T1/de not_active IP Right Cessation
- 1995-10-23 DE DE69535461T patent/DE69535461T2/de not_active Expired - Lifetime
- 1995-10-23 US US08/546,998 patent/US6211244B1/en not_active Expired - Lifetime
- 1995-10-23 CZ CZ19971182A patent/CZ290670B6/cs not_active IP Right Cessation
- 1995-10-23 UA UA97052226A patent/UA55374C2/uk unknown
- 1995-10-23 HU HU9802491A patent/HU228150B1/hu active Protection Beyond IP Right Term
- 1995-10-23 AU AU41957/96A patent/AU709303B2/en not_active Expired
- 1995-10-23 CA CA002202879A patent/CA2202879C/en not_active Expired - Lifetime
- 1995-10-23 ES ES01204920T patent/ES2234768T3/es not_active Expired - Lifetime
- 1995-10-23 RU RU97108069/04A patent/RU2195446C2/ru not_active IP Right Cessation
- 1995-10-23 WO PCT/US1995/013704 patent/WO1996012697A2/en active IP Right Grant
- 1995-10-23 CN CNB951970054A patent/CN1147459C/zh not_active Expired - Lifetime
- 1995-10-23 DE DE69533948T patent/DE69533948T2/de not_active Expired - Lifetime
- 1995-10-23 PT PT01204920T patent/PT1203761E/pt unknown
- 1995-10-23 PL PL95319812A patent/PL183499B1/pl unknown
- 1995-10-23 HU HU0700718A patent/HU229474B1/hu unknown
- 1995-10-23 CN CNB021302251A patent/CN1312116C/zh not_active Expired - Fee Related
- 1995-10-23 AT AT01204920T patent/ATE287390T1/de active
- 1995-10-23 EP EP95940547A patent/EP0787122B9/en not_active Expired - Lifetime
- 1995-10-23 DE DE200512000033 patent/DE122005000033I1/de active Pending
- 1995-10-23 EP EP01204920A patent/EP1203761B1/en not_active Expired - Lifetime
- 1995-10-23 DK DK01204920T patent/DK1203761T3/da active
- 1995-10-23 BR BRPI9509411 patent/BRPI9509411B8/pt active IP Right Grant
- 1995-10-23 KR KR1019970702598A patent/KR100293621B1/ko not_active IP Right Cessation
- 1995-10-23 DE DE1995633948 patent/DE122005000033I2/de active Active
- 1995-10-23 JP JP8514118A patent/JP2882882B2/ja not_active Expired - Lifetime
- 1995-10-23 EP EP04026530A patent/EP1553078A1/en not_active Withdrawn
- 1995-10-23 KR KR10-2000-7003440A patent/KR100403094B1/ko not_active IP Right Cessation
- 1995-10-23 ES ES95940547T patent/ES2285707T3/es not_active Expired - Lifetime
- 1995-11-03 TW TW092127732A patent/TW200402407A/zh unknown
- 1995-11-03 TW TW084111615A patent/TW568896B/zh not_active IP Right Cessation
-
1998
- 1998-01-29 JP JP01656398A patent/JP4002338B2/ja not_active Expired - Fee Related
- 1998-02-03 HK HK98100781A patent/HK1002454A1/xx not_active IP Right Cessation
-
1999
- 1999-11-12 HK HK99105216A patent/HK1020041A1/xx not_active IP Right Cessation
-
2001
- 2001-10-21 CZ CZ20014662A patent/CZ292709B6/cs not_active IP Right Cessation
-
2002
- 2002-10-31 HK HK02107939.7A patent/HK1046900B/zh not_active IP Right Cessation
-
2003
- 2003-07-12 HK HK03105050.3A patent/HK1052685A1/zh unknown
-
2005
- 2005-06-10 NL NL300199C patent/NL300199I2/nl unknown
- 2005-06-30 FR FR05C0029C patent/FR05C0029I2/fr active Active
- 2005-07-18 LU LU91182C patent/LU91182I2/fr unknown
-
2007
- 2007-02-22 JP JP2007042364A patent/JP4353985B2/ja not_active Expired - Fee Related
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001106661A (ja) * | 1999-08-04 | 2001-04-17 | Sumitomo Chem Co Ltd | アミン化合物、中間体、製造法および光学分割剤 |
JP4595178B2 (ja) * | 1999-08-04 | 2010-12-08 | 住友化学株式会社 | アミン化合物、中間体、製造法および光学分割剤 |
JP2005530811A (ja) * | 2002-05-23 | 2005-10-13 | アムジエン・インコーポレーテツド | カルシウム受容体修飾物質 |
JP4642461B2 (ja) * | 2002-05-23 | 2011-03-02 | アムジエン・インコーポレーテツド | カルシウム受容体修飾物質 |
JP2009507017A (ja) * | 2005-09-02 | 2009-02-19 | アムジエン・インコーポレーテツド | 腸液バランスを調節する方法 |
JP2009534425A (ja) * | 2006-04-20 | 2009-09-24 | アムゲン インコーポレイティッド | 安定乳化製剤 |
WO2009107579A1 (ja) * | 2008-02-25 | 2009-09-03 | 味の素株式会社 | コク味付与剤 |
JP2012523418A (ja) * | 2009-04-09 | 2012-10-04 | コグニション セラピューティクス インク. | 認知機能低下の阻害剤 |
WO2010150837A1 (ja) * | 2009-06-25 | 2010-12-29 | 第一三共株式会社 | インドリン誘導体 |
JP2015528462A (ja) * | 2012-08-27 | 2015-09-28 | ルピン・リミテッドLupin Limited | カルシウム感知受容体モジュレーターとしてのアリールアルキルアミン化合物 |
US10207991B2 (en) | 2014-01-31 | 2019-02-19 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10513436A (ja) | カルシウム受容体活性化合物 | |
US6011068A (en) | Calcium receptor-active molecules | |
US6313146B1 (en) | Calcium receptor-active molecules | |
US5688938A (en) | Calcium receptor-active molecules | |
US5763569A (en) | Calcium receptor-active molecules | |
JP2728564B2 (ja) | カルシウム受容体活性化分子 | |
US5858684A (en) | Method of screening calcium receptor-active molecules | |
US5962314A (en) | Calcium receptor-active molecules | |
US6001884A (en) | Calcium receptor-active molecules | |
US20130190407A1 (en) | Calcium receptor-active molecules | |
KR100300450B1 (ko) | 칼슘 수용체-활성 화합물 | |
AU747853B2 (en) | Calcium receptor-active compounds | |
AU673500C (en) | Calcium receptor active molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
R150 | Certificate of patent or registration of utility model |
Ref document number: 2882882 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S211 | Written request for registration of transfer of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314211 |
|
S633 | Written request for registration of reclamation of name |
Free format text: JAPANESE INTERMEDIATE CODE: R314633 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S211 | Written request for registration of transfer of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314211 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R314533 |
|
S633 | Written request for registration of reclamation of name |
Free format text: JAPANESE INTERMEDIATE CODE: R314633 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S303 | Written request for registration of pledge or change of pledge |
Free format text: JAPANESE INTERMEDIATE CODE: R316303 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
S303 | Written request for registration of pledge or change of pledge |
Free format text: JAPANESE INTERMEDIATE CODE: R316303 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S303 | Written request for registration of pledge or change of pledge |
Free format text: JAPANESE INTERMEDIATE CODE: R316313 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S303 | Written request for registration of pledge or change of pledge |
Free format text: JAPANESE INTERMEDIATE CODE: R316313 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S211 | Written request for registration of transfer of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314211 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |